The Peking University People's Hospital, Beijing, Beijng, China (Recruiting) - 31 Oct `25VC005 tablets for nonsegmental vitiligo

VC005 tablets for nonsegmental vitiligo

Official title: A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo

Status: Recruiting now

Description:

Jiangsu vcare pharmaceutical technology co., LTD plans to enroll about 120 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanocyte damage and help skin regain color. Possible effects may include headache, stomach upset, skin irritation, and infections; the full safety profile is still being studied. People ages 18 to 75 may qualify. The study is recruiting at one listed site in China.

Start date: October 31, 2025

Completion date: August 30, 2027

Organizer: Jiangsu vcare pharmaceutical technology co., LTD

Contact: xiaojuan lai

Tel.: 1 535 816 045 8

Email: lai_xiaojuan@vcarepharmatech.com

Link: https://clinicaltrials.gov/study/NCT07172347

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference VC005 tablets for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions